Theranos No. 2? Startup That Charges $8K To Inject You With Young Blood Now Doing Business In 5 U.S. Cities
Can young blood transfusions make you younger? The founder of the new startup Ambrosia, Jesse Karmazin, claims it does and is banking on people lining up for this controversial procedure.
Has Karmazin hit on the fountain of youth? Or is his company another Theranos? Theranos, as you recall, was a privately held health technology corporation founded by Elizabeth Holmes that claimed to have created a breakthrough blood test that only needed very small amounts of blood. In the end it, it was all proved to be false — but not have the company and founder racked in millions of dollars from investors.
Listen to GHOGH with Jamarlin Martin | Episode 67: Jamarlin Martin Jamarlin goes solo to discuss the NFL’s entertainment and “social justice” deal with Jay-Z. We look back at the Barclays gentrification issue in the documentary “A Genius Leaves The Hood: The Unauthorized Story of Jay-Z.”
Ambrosia is still young, having been founded about three years ago and the verdict hasn’t been delivered one way or the other. But here’s what the company claims it des: for $8,000 it can to fill your veins with young blood (drawn from people aged 16-25) and this will make you look and feel younger. The startup says it is currently operating in five cities across the U.S. — Los Angeles; San Francisco; Tampa, Florida; Omaha, Nebraska; and Houston, Texas. Ambrosia offers two options: 1 liter of young blood for $8,000, or 2 liters for $12,000.
And, you can pay via PayPal payments.
While Ambrosia claims its transfusions will help fight aging by rejuvenating the body’s organs, there’s little to no evidence this works and some in the medical field say it could be dangerous.
“But because the Food and Drug Administration has approved blood transfusions, Ambrosia’s approach has been able to continue as an off-label treatment,” Business Insider reported.
According to the company it has infused nearly 150 people, ranging in age from 35 to 92, with the blood of younger donors. Of those, Cavalier said, 81 took part in its clinical trial. Even those who participated in the trials had to pay $8,000 for the transfusions.
“The trial, which involved giving patients 1.5 liters of plasma from a donor between the ages of 16 and 25 over two days, was conducted with David Wright, a physician who owns a private intravenous-therapy center in Monterey, California. Before and after the infusions, participants’ blood was tested for a handful of biomarkers, or measurable biological substances and processes thought to provide a snapshot of health and disease,” Business Insider reported.
“The trial was an investigational study,” Cavalier said. “We saw some interesting things, and we do plan to publish that data. And we want to begin to open clinics where the treatment will be made available.”